
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial
Keywords: پاسخ پایدار ویروسی; Clinical Trial; Direct-Acting Antiviral; DAA; Non-Genotype 1 HCV; CI; confidence interval; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; RAS; resistance-associated substitution; SVR; sustained virologic response; SVR12; sustained virologic r